Expression and diagnostic value of CCT3 and IQGAP3 in hepatocellular carcinoma.
Expression and diagnostic value of CCT3 and IQGAP3 in hepatocellular carcinoma.
复制标题
DOI：
10.1186/s12935-016-0332-3
复制
发表时间：
2016
影响因子：
5.8
通讯作者：
Lv X
中科院分区：
文献类型：
--
作者：
Qian EN;Han SY;Ding SZ;Lv X
目的探讨血浆伴侣蛋白（CCT 3）和GTP酶激活蛋白（IQGAP 3）作为肝细胞癌（HCC）筛查和诊断的生物标志物的价值。收集126例HCC合并HCC患者、88例肝硬化患者和50例健康志愿者的血样，检测血浆甲胎蛋白（AFP）、CCT 3和IQGAP 3水平。采用酶联免疫吸附试验（ELISA）检测血浆AFP、CCT 3和IQGAP 3蛋白水平。在肝癌患者血浆中，CCT 3和IQGAP 3均明显高于肝硬化患者和健康对照组（P < 0.01）。CCT 3和IQGAP 3蛋白水平与HCC病因、肿瘤大小、TNM分期和Child-Pugh分级相关。与AFP相比，CCT 3蛋白对HCC的诊断敏感性更高（87.3%比69.8%）。此外，CCT 3和IQGAP 3蛋白能够补充AFP检测AFP阴性肝癌患者，灵敏度和特异性分别为92.1%和70.5%以及81.6%和71.6%。在小肝癌组中，CCT 3和IQGAP 3蛋白的敏感性分别为76.6%和74.5%。AFP + CCT 3 + IQGAP 3联合检测的鉴别能力（0.954）显著上级AFP单独检测（0.815; P < 0.01）。CCT 3和IQGAP 3是HCC筛查和诊断的新的互补生物标志物，特别是对于AFP阴性和小HCC患者。
To evaluate plasma chaperonin containing TCP1 complex subunit 3 (CCT3) and IQ-motif-containing GTPase-activating protein-3 (IQGAP3) as biomarker for hepatocellular carcinoma (HCC) screening and diagnosis. Blood samples were collected from 126 HCC patients with HCC, 88 patients with cirrhosis and 50 healthy volunteers to detect plasma α-fetoprotein (AFP), CCT3 and IQGAP3 levels. Plasma AFP, CCT3 and IQGAP3 protein levels were measured by enzyme linked immunosorbent assay (ELISA). In the plasma of HCC patients, both CCT3 and IQGAP3 were significantly higher than in patients with cirrhosis and in healthy controls (P < 0.01). CCT3 and IQGAP3 protein level correlated well with HCC etiology, tumor size, TNM stage, and child-pugh classification. CCT3 protein had higher sensitivity in the diagnosis of HCC when compared with AFP (87.3 vs 69.8 %). In addition, CCT3 and IQGAP3 protein were able to complement AFP in detecting AFP-negative HCC patients with sensitivity and specificity of 92.1 and 70.5 % and 81.6 and 71.6 %, respectively. In the small HCC group, CCT3 and IQGAP3 protein had sensitivity of 76.6 and 74.5 %, respectively. The combination of AFP + CCT3 + IQGAP3 (0.954) had significantly superior discriminative ability than AFP alone (0.815; P < 0.01). CCT3 and IQGAP3 are novel complementary biomarkers for HCC screening and diagnosis, especially for AFP-negative and small HCC patients.